Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

被引：316
作者：
Lonergan, KM
Iliopoulos, O
Ohh, M
Kamura, T
Conaway, RC
Conaway, JW
Kaelin, WG
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA
[4] Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA
[5] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA
来源：
MOLECULAR AND CELLULAR BIOLOGY | 1998年 / 18卷 / 02期
关键词：
D O I：
10.1128/MCB.18.2.732
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The von Hippel-Lindau tumor suppressor protein(pVHL) binds to elongins B and C and posttranscriptionally regulates the accumulation of hypoxia-inducible mRNAs under normoxic (21% O-2) conditions. Here we report that pVHL binds, via elongin C, to the human homolog of the Caenorhabditis elegans Cul2 protein. Coimmunoprecipitation and chromatographic copurification data suggest that pVHL-Cul2 complexes exist in native cells. pVHL mutants that were unable to bind to complexes containing elongin C and Cul2 were likewise unable to inhibit the accumulation of hypoxia-inducible mRNAs. A model for the regulation of hypoxia-inducible mRNAs by pVHL is presented based on the apparent similarity of elongin C and Cul2 to Skp1 and Cdc53, respectively. These latter proteins form complexes that target specific proteins for ubiquitin-dependent proteolysis.
引用
收藏
页码：732 / 741
页数：10
相关论文
共 52 条
  • [1] [Anonymous], 1992, MENDELIAN INHERITANC
  • [2] [Anonymous], 1988, Antibodies: A Laboratory Manual
  • [3] The inducible elongin A elongation activation domain: Structure, function and interaction with the elongin BC complex
    Aso, T
    Haque, D
    Barstead, RJ
    Conaway, RC
    Conaway, JW
    [J]. EMBO JOURNAL, 1996, 15 (20) : 5557 - 5566
  • [4] SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box
    Bai, C
    Sen, P
    Hofmann, K
    Ma, L
    Goebl, M
    Harper, JW
    Elledge, SJ
    [J]. CELL, 1996, 86 (02) : 263 - 274
  • [5] VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) GENE IS EXPRESSED DIFFERENTIALLY IN NORMAL-TISSUES, MACROPHAGES, AND TUMORS
    BERSE, B
    BROWN, LF
    VANDEWATER, L
    DVORAK, HF
    SENGER, DR
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (02) : 211 - 220
  • [6] Conaway RC, 1996, METHOD ENZYMOL, V273, P194
  • [7] CONAWAY RC, UNPUB
  • [8] Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
    Corless, CL
    Kibel, AS
    Iliopoulos, O
    Kaelin, WG
    [J]. HUMAN PATHOLOGY, 1997, 28 (04) : 459 - 464
  • [9] INHIBITION OF TRANSCRIPTION ELONGATION BY THE VHL TUMOR-SUPPRESSOR PROTEIN
    DUAN, DR
    PAUSE, A
    BURGESS, WH
    ASO, T
    CHEN, DYT
    GARRETT, KP
    CONAWAY, RC
    CONAWAY, JW
    LINEHAN, WM
    KLAUSNER, RD
    [J]. SCIENCE, 1995, 269 (5229) : 1402 - 1406
  • [10] SOMATIC MUTATIONS OF THE VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE IN NONFAMILIAL CLEAR-CELL RENAL-CARCINOMA
    FOSTER, K
    PROWSE, A
    VANDENBERG, A
    FLEMING, S
    HULSBEEK, MMF
    CROSSEY, PA
    RICHARDS, FM
    CAIRNS, P
    AFFARA, NA
    FERGUSONSMITH, MA
    BUYS, CHCM
    MAHER, ER
    [J]. HUMAN MOLECULAR GENETICS, 1994, 3 (12) : 2169 - 2173
123456